October 21, 2026
More than 30 years after its discovery, the mechanism of immune checkpoint protein LAG3 is incompletely understood, despite being a target of an FDA-approved immunotherapy, according to a new article published in Nature Reviews Immunology.
October 20, 2026
A new review, published in Immunological Reviews, from the Joglekar Lab highlights how post-translationally modified proteins (PTMs)—those that have been chemically modified after synthesis—can stimulate autoimmune disorders such as type 1 diabetes, rheumatoid arthritis, and celiac disease and describes current and emerging tools to identify these diverse proteins.
August 19, 2026
A new review published in Trends in Immunology, synthesizes current evidence that the microbiome is an important mediator of exercise-driven benefits to the immune system, identifies challenges and limitations in the field, and lays out questions that still need to be addressed.
